Bayer (BAYN) Given a €85.00 Price Target at Barclays
Bayer (FRA:BAYN) has been assigned a €85.00 ($98.84) price target by Barclays in a research note issued on Tuesday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the healthcare company’s stock. Barclays‘s target price would suggest a potential upside of 51.70% from the company’s previous close.
Several other analysts have also recently weighed in on the stock. UBS Group set a €110.00 ($127.91) price target on shares of Bayer and gave the company a “buy” rating in a research note on Thursday, March 28th. Baader Bank set a €123.00 ($143.02) price target on shares of Bayer and gave the company a “buy” rating in a research note on Monday, April 29th. Goldman Sachs Group set a €77.00 ($89.53) price target on shares of Bayer and gave the company a “buy” rating in a research note on Tuesday, April 23rd. HSBC set a €76.00 ($88.37) price target on shares of Bayer and gave the company a “neutral” rating in a research note on Thursday, March 21st. Finally, Independent Research set a €52.50 ($61.05) price objective on shares of Bayer and gave the stock a “sell” rating in a research report on Friday, March 29th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of €81.67 ($94.97).
Bayer stock opened at €56.03 ($65.15) on Tuesday. Bayer has a 1-year low of €91.58 ($106.49) and a 1-year high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Read More: What are economic reports?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.